TY - JOUR
T1 - Dementia risk reduction
T2 - why haven't the pharmacological risk reduction trials worked? An in-depth exploration of seven established risk factors
AU - Peters, Ruth
AU - Breitner, John
AU - James, Sarah
AU - Jicha, Gregory A.
AU - Meyer, Pierre Francois
AU - Richards, Marcus
AU - Smith, A. David
AU - Yassine, Hussein N.
AU - Abner, Erin
AU - Hainsworth, Atticus H.
AU - Kehoe, Patrick G.
AU - Beckett, Nigel
AU - Weber, Christopher
AU - Anderson, Craig
AU - Anstey, Kaarin J.
AU - Dodge, Hiroko H.
N1 - Publisher Copyright:
© 2021 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association.
PY - 2021
Y1 - 2021
N2 - Identifying the leading health and lifestyle factors for the risk of incident dementia and Alzheimer's disease has yet to translate to risk reduction. To understand why, we examined the discrepancies between observational and clinical trial evidence for seven modifiable risk factors: type 2 diabetes, dyslipidemia, hypertension, estrogens, inflammation, omega-3 fatty acids, and hyperhomocysteinemia. Sample heterogeneity and paucity of intervention details (dose, timing, formulation) were common themes. Epidemiological evidence is more mature for some interventions (eg, non-steroidal anti-inflammatory drugs [NSAIDs]) than others. Trial data are promising for anti-hypertensives and B vitamin supplementation. Taken together, these risk factors highlight a future need for more targeted sample selection in clinical trials, a better understanding of interventions, and deeper analysis of existing data.
AB - Identifying the leading health and lifestyle factors for the risk of incident dementia and Alzheimer's disease has yet to translate to risk reduction. To understand why, we examined the discrepancies between observational and clinical trial evidence for seven modifiable risk factors: type 2 diabetes, dyslipidemia, hypertension, estrogens, inflammation, omega-3 fatty acids, and hyperhomocysteinemia. Sample heterogeneity and paucity of intervention details (dose, timing, formulation) were common themes. Epidemiological evidence is more mature for some interventions (eg, non-steroidal anti-inflammatory drugs [NSAIDs]) than others. Trial data are promising for anti-hypertensives and B vitamin supplementation. Taken together, these risk factors highlight a future need for more targeted sample selection in clinical trials, a better understanding of interventions, and deeper analysis of existing data.
UR - http://www.scopus.com/inward/record.url?scp=85123883344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123883344&partnerID=8YFLogxK
U2 - 10.1002/trc2.12202
DO - 10.1002/trc2.12202
M3 - Review article
AN - SCOPUS:85123883344
SN - 2352-8737
VL - 7
JO - Alzheimer's and Dementia: Translational Research and Clinical Interventions
JF - Alzheimer's and Dementia: Translational Research and Clinical Interventions
IS - 1
M1 - e12202
ER -